9 research outputs found
Augmented antipsychotic therapy with pantogam active in patients with schizophrenia
Objective β to study the efficacy of the GABA-ergic drug pantogam active (D-, L-gopantenic acid) in patients with schizophrenia treated with typical neuroleptics and to assess the rate of treatment response and tolerability of the drug. Material and methods. A sample consisted of 70 patients with schizophrenia stratified into main (n=35) and control (n=35) groups. All patients received one of typical antipsychotics (haloperidol, zuclopenthixol, promazine or perphenazine). Patients of the main group received in addition pantogam active in dose of 1200-1800 mg daily. The maximum allowed dose of 1800 mg daily was used in 62.9% of the patients. Results and conclusion: The long-term combined therapy with the addition of D-, L-gopantenic acid (pantogam activ) allowed to achieve clinical improvement earlier (on 8th week in the main group versus 16th week in the control group). The frequency and severity of secondary negative symptoms associated with antipsychotic therapy were decreased as well. The high efficacy and tolerability of the combined therapy allow to improve quality of life in patients with schizophrenia and their compliance to treatment as well as to reduce costs of medical care. Β© 2015, Media Sphera. All Rights Reserved
Antidepressant therapy in patients with cardiovascular diseases
Depression is the most common form of mental illness in patients with cardiovascular diseases (CVD). Depression and CVD can worsen the clinical and dynamic characteristics of each other. The timely detection and adequate psychopharmacotherapy of depressive states in patients with CVD are of great clinical, therapeutic, and prognostic importance. Anti-antidepressant therapy promotes a more pronounced somatic stabilizing effect in patients with CVD. Adverse events to the use of antidepressants in patients with CVD may be associated with their negative effect on the hepatic cytochrome CYP450 isoenzymes involved in the metabolism of various drugs. The authors' own data of clinical psychopharmacotherapeutic studies and the results of meta-analyses indicate the high efficiency and good tolerability of agomelatine, an antidepressant with an innovative mechanism of action, in a wide range of patients. Β© 2019 Ima-Press Publishing House. All rights reserved
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²Π°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½Π° ΠΏΡΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΡΡ , ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΡ Ρ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ
Objective. To investigate the efficacy and tolerability of monotherapy with agomelatine (valdoxan) in depressive patients with marked cognitive impairment. Material and methods. Thirty-five patients (women 77.1%) were recruited to participate in the study. Mean age of patients was 48.9Β±3.5 years. The following scales and cognitive tests were used: HAM-21, CGI, HADS, MMSE, the Stroop task, the Rey test, RAVLT. Effective therapeutic doses of valdoxan were 25mg per day in 77.1% of patients, 50 mg per day beginning from week 2 in 22.9%. Cognitive impairment was found in astheno-apathic depression (51.4%), anxiety-hypochondriacal depression (28.6%), anhedonic depression (5.7%). Results. The results showed that 74.3% of patients were responders and 51.4% were in remission. The dynamic of cognitive impairment demonstrated the positive effect of treatment with agomelatine (valdoxan). Beneficial safety profile of valdoxan was confirmed. Conclusion. Valdoxan is the effective and relatively safe antidepressant; it can be recommended for treatment of depression with cognitive impairment in therapeutic doses for at least 6 weeks.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²Π°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½ΠΎΠΌ (Π°Π³ΠΎΠΌΠ΅Π»Π°ΡΠΈΠ½) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌΠΈ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 35 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠ· ΠΊΠΎΡΠΎΡΡΡ
77,1% Π±ΡΠ»ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½Ρ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 48,9Β±3,5 Π³ΠΎΠ΄Π°). ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠΊΠ°Π»Ρ ΠΠ°ΠΌΠΈΠ»ΡΡΠΎΠ½Π° (HAM-21), ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΏΠ΅ΡΠ°ΡΠ»Π΅Π½ΠΈΡ (CGI), Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ ΡΡΠ΅Π²ΠΎΠ³ΠΈ ΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ (HADS), ΡΠΊΠ°Π»Ρ MMSE, ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅ΡΡΡ (ΡΠ΅ΡΡ Π‘ΡΡΡΠΏΠ°, ΡΠ΅ΡΡ Π Π΅Ρ Π½Π° ΡΠ»ΡΡ
ΠΎΡΠ΅ΡΠ΅Π²ΠΎΠ΅ Π·Π°ΡΡΠΈΠ²Π°Π½ΠΈΠ΅, RAVLT). ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΎΠ·Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 25 ΠΌΠ³/ΡΡΡ Ρ 77,1% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², 50 ΠΌΠ³/ΡΡΡ Π½Π°ΡΠΈΠ½Π°Ρ ΡΠΎ 2-ΠΉ Π½Π΅Π΄Π΅Π»ΠΈ β Ρ 22,9% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΠΏΡΠΈ Π°ΡΡΠ΅Π½ΠΎ-Π°ΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
(51,4% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ), ΡΡΠ΅Π²ΠΎΠΆΠ½ΠΎ-ΠΈΠΏΠΎΡ
ΠΎΠ½Π΄ΡΠΈΡΠ΅ΡΠΊΠΈΡ
(28,6%), Π°Π½Π³Π΅Π΄ΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
(5,7%) Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΡΡ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅ΡΠΏΠΎΠ½Π΄Π΅ΡΠ°ΠΌΠΈ ΠΎΠΊΠ°Π·Π°Π»ΠΈΡΡ 74,3% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π£ 51,4% Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠ°ΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΡ
ΡΡΠ½ΠΊΡΠΈΠΉ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΌ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΡΡΡΠ΅ΠΊΡΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΉ, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΠΈΡ
ΡΡ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ, Π² ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄ΠΎΠ·Π°Ρ
ΠΊΡΡΡΠΎΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 6 Π½Π΅Π΄
Augmented antipsychotic therapy with pantogam active in patients with schizophrenia
Objective β to study the efficacy of the GABA-ergic drug pantogam active (D-, L-gopantenic acid) in patients with schizophrenia treated with typical neuroleptics and to assess the rate of treatment response and tolerability of the drug. Material and methods. A sample consisted of 70 patients with schizophrenia stratified into main (n=35) and control (n=35) groups. All patients received one of typical antipsychotics (haloperidol, zuclopenthixol, promazine or perphenazine). Patients of the main group received in addition pantogam active in dose of 1200-1800 mg daily. The maximum allowed dose of 1800 mg daily was used in 62.9% of the patients. Results and conclusion: The long-term combined therapy with the addition of D-, L-gopantenic acid (pantogam activ) allowed to achieve clinical improvement earlier (on 8th week in the main group versus 16th week in the control group). The frequency and severity of secondary negative symptoms associated with antipsychotic therapy were decreased as well. The high efficacy and tolerability of the combined therapy allow to improve quality of life in patients with schizophrenia and their compliance to treatment as well as to reduce costs of medical care. Β© 2015, Media Sphera. All Rights Reserved
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²Π°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½Π° ΠΏΡΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΡΡ , ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΡ Ρ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ
Objective. To investigate the efficacy and tolerability of monotherapy with agomelatine (valdoxan) in depressive patients with marked cognitive impairment. Material and methods. Thirty-five patients (women 77.1%) were recruited to participate in the study. Mean age of patients was 48.9Β±3.5 years. The following scales and cognitive tests were used: HAM-21, CGI, HADS, MMSE, the Stroop task, the Rey test, RAVLT. Effective therapeutic doses of valdoxan were 25mg per day in 77.1% of patients, 50 mg per day beginning from week 2 in 22.9%. Cognitive impairment was found in astheno-apathic depression (51.4%), anxiety-hypochondriacal depression (28.6%), anhedonic depression (5.7%). Results. The results showed that 74.3% of patients were responders and 51.4% were in remission. The dynamic of cognitive impairment demonstrated the positive effect of treatment with agomelatine (valdoxan). Beneficial safety profile of valdoxan was confirmed. Conclusion. Valdoxan is the effective and relatively safe antidepressant; it can be recommended for treatment of depression with cognitive impairment in therapeutic doses for at least 6 weeks.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²Π°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½ΠΎΠΌ (Π°Π³ΠΎΠΌΠ΅Π»Π°ΡΠΈΠ½) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌΠΈ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 35 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠ· ΠΊΠΎΡΠΎΡΡΡ
77,1% Π±ΡΠ»ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½Ρ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 48,9Β±3,5 Π³ΠΎΠ΄Π°). ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠΊΠ°Π»Ρ ΠΠ°ΠΌΠΈΠ»ΡΡΠΎΠ½Π° (HAM-21), ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΏΠ΅ΡΠ°ΡΠ»Π΅Π½ΠΈΡ (CGI), Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ ΡΡΠ΅Π²ΠΎΠ³ΠΈ ΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ (HADS), ΡΠΊΠ°Π»Ρ MMSE, ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅ΡΡΡ (ΡΠ΅ΡΡ Π‘ΡΡΡΠΏΠ°, ΡΠ΅ΡΡ Π Π΅Ρ Π½Π° ΡΠ»ΡΡ
ΠΎΡΠ΅ΡΠ΅Π²ΠΎΠ΅ Π·Π°ΡΡΠΈΠ²Π°Π½ΠΈΠ΅, RAVLT). ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΎΠ·Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 25 ΠΌΠ³/ΡΡΡ Ρ 77,1% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², 50 ΠΌΠ³/ΡΡΡ Π½Π°ΡΠΈΠ½Π°Ρ ΡΠΎ 2-ΠΉ Π½Π΅Π΄Π΅Π»ΠΈ β Ρ 22,9% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΠΏΡΠΈ Π°ΡΡΠ΅Π½ΠΎ-Π°ΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
(51,4% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ), ΡΡΠ΅Π²ΠΎΠΆΠ½ΠΎ-ΠΈΠΏΠΎΡ
ΠΎΠ½Π΄ΡΠΈΡΠ΅ΡΠΊΠΈΡ
(28,6%), Π°Π½Π³Π΅Π΄ΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
(5,7%) Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΡΡ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π΅ΡΠΏΠΎΠ½Π΄Π΅ΡΠ°ΠΌΠΈ ΠΎΠΊΠ°Π·Π°Π»ΠΈΡΡ 74,3% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π£ 51,4% Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠ°ΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΡ
ΡΡΠ½ΠΊΡΠΈΠΉ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΌ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΡΡΡΠ΅ΠΊΡΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΉ, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΠΈΡ
ΡΡ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ, Π² ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄ΠΎΠ·Π°Ρ
ΠΊΡΡΡΠΎΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 6 Π½Π΅Π΄
Π’Π΅ΡΠ°ΠΏΠΈΡ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ², ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΡ Ρ ΡΠΈΡΠΊΠ°Π½Π½ΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΠΈΡΠΌΠ°ΠΌΠΈ
Studies of efficacy of agomelatine in treatment of depressions with seasonal rhythm in the framework of BAD are almost lacked. This is the study of efficacy and tolerability of agomelatine in treatment of depressions with circannual rhythms in the framework of BAD (n=35) and SAD (n=35). Agomelatine was effective in 82.9% patients with SAD and in 71.4% patients with BAD. Predictors of inefficacy in both groups were lack of circadian rhythm and inefficacy of previous treatment. Predictors of inefficacy in SAD patients were monopolar progress of disease, elongation of depressive phases, schizotypal disorder; in BAD patients - less of 5 previous seasonal depressive phases, lack of improvement in first two weeks of treatment, sadness and anxiety. Agomelatine has favorable profile of safety and tolerability.ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°Π³ΠΎΠΌΠ΅Π»Π°ΡΠΈΠ½Π° ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΉ Ρ ΡΠ΅Π·ΠΎΠ½Π½ΡΠΌ ΡΠΈΡΠΌΠΎΠΌ Π² ΡΠ°ΠΌΠΊΠ°Ρ
Π±ΠΈΠΏΠΎΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π° (ΠΠΠ ) ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΡΡΡΡΡΡΠ²ΡΡΡ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π³ΠΎΠΌΠ΅Π»Π°ΡΠΈΠ½ΠΎΠΌ (ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΠ°Π»ΡΠ΄ΠΎΠΊΡΠ°Π½) Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΉ, ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΡ
Ρ ΡΠ΅Π·ΠΎΠ½Π½ΡΠΌΠΈ ΡΠΈΡΠΊΠ°Π½Π½ΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΡΠΈΡΠΌΠ°ΠΌΠΈ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΡΠ΅Π·ΠΎΠ½Π½ΠΎΠ³ΠΎ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π° - Π‘ΠΠ (n=35) ΠΈ ΠΠΠ (n=35). Π Ρ
ΠΎΠ΄Π΅ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΉ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ ΡΠΈΠΌΠΎΠ»Π΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ Π°Π³ΠΎΠΌΠ΅Π»Π°ΡΠΈΠ½Π° Ρ 82,9% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘ΠΠ ΠΈ 71,4% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ . ΠΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠ²Π»ΡΠ»ΠΈΡΡ: ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΡΠΌΠ°, Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠΈΡ
ΠΊΡΡΡΠΎΠ² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ; Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘ΠΠ - ΠΌΠΎΠ½ΠΎΠΏΠΎΠ»ΡΡΠ½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅, ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΎΡ Π³ΠΎΠ΄Π° ΠΊ Π³ΠΎΠ΄Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅Π·ΠΎΠ½Π½ΡΡ
Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΉ ΠΈ ΠΈΡ
ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΡ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΡΠΈΠ·ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°; Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ - ΠΌΠ΅Π½Π΅Π΅ 5 ΡΠ΅Π·ΠΎΠ½Π½ΡΡ
ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅, ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ²ΡΡ
2 Π½Π΅Π΄ ΠΏΡΠΈΠ΅ΠΌΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, Π½Π°Π»ΠΈΡΠΈΠ΅ Π² ΡΡΡΡΠΊΡΡΡΠ΅ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠΎΡΠΊΠ»ΠΈΠ²ΠΎΠ³ΠΎ ΠΈΠ»ΠΈ ΡΡΠ΅Π²ΠΎΠΆΠ½ΠΎΠ³ΠΎ Π°ΡΡΠ΅ΠΊΡΠ°. ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ
Optimization of the treatment of anxiety disorders with selank
Objective. To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Material and methods. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clinically and with HDRS, CGI and Spilberger scales. Tolerability was evaluated using the UKU scale. Stroop test and verbal fluency test were used. Quality of life was assessed with the SF-36. Results. The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. The combined treatment decreased the level of undesirable side-effects of phenazepam (attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism) during the course of treatment and after the tranquilizer withdrawal. Taken together, the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam. Conclusion. The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank. Β© 2015, Media Sphera. All rights reserved
Optimization of the treatment of anxiety disorders with selank
Objective. To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Material and methods. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clinically and with HDRS, CGI and Spilberger scales. Tolerability was evaluated using the UKU scale. Stroop test and verbal fluency test were used. Quality of life was assessed with the SF-36. Results. The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. The combined treatment decreased the level of undesirable side-effects of phenazepam (attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism) during the course of treatment and after the tranquilizer withdrawal. Taken together, the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam. Conclusion. The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank. Β© 2015, Media Sphera. All rights reserved
Depressions with eating disorders: clinical manifestations and therapy [ΠΠ΅ΠΏΡΠ΅ΡΡΠΈΠΈ Ρ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌΠΈ ΠΏΠΈΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ: ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡ]
Depression is a common comorbid diagnosis in patients with eating disorders (EDs). The development of pathogenetic therapy for depression with EDs is far from being completed. The objective of the psychopharmacotherapeutic study was to evaluate the efficacy and tolerability of melatonergic monotherapy with the antidepressant agomelatine (25β50 mg/day at night) for depressions with two ED variants: hyperphagic (n=32) and hypo- and aphagic (n=31) EDs. Patients and methods. The investigation enrolled patients of both sexes, aged 18 to 65 years. The investigators performed clinical psychopathological and experimental psychological studies, as well as psychometric examination using the 21-item Hamilton Depression Rating Scale (HDRS-21), the Clinical Global Impression (CGI), the Supplemental Hospital Offset Payment Program (SHOPP), the Dutch Eating Behavior Questionnaire (DEBQ), and statistical data processing. Results and discussion. There was a significant pronounced antidepressant effect of 6-week agomelatine therapy for depressions occurring with different ED variants both in the pattern of the depressive symptom complex and in that of concurrent with and preceding the latter. At the same time, the efficacy of the drug did not depend on the clinical presentations of the leading hypothymic syndrome, the variants of EDs, and the duration of actual depression. However, by the end of the study period, a larger effect was achieved in the therapy for depressions with the hyperphagic variant of EDs, as well as in patients with EDs manifesting in the pattern of depressive symptom complex. Agomelatine has a favorable tolerance profile. BMI tends to become normal in patients with different variants of EDs during the therapy. The adverse events are transient and/or unclear; they do not require therapy discontinuation. Conclusion. Agomelatine is an effective and relatively safe drug that can be recommended to treat depressions concurrent with EDs in therapeutic dosages for at least 6 weeks. Β© 2020 Ima-Press Publishing House. All rights reserved